Last reviewed · How we verify
GcMAF injections (100 ng)
GcMAF (Gc-protein derived macrophage activating factor) activates macrophages to enhance immune surveillance and anti-tumor activity.
GcMAF (Gc-protein derived macrophage activating factor) activates macrophages to enhance immune surveillance and anti-tumor activity. Used for Advanced cancer (various solid tumors and hematologic malignancies), Chronic viral infections.
At a glance
| Generic name | GcMAF injections (100 ng) |
|---|---|
| Sponsor | S.LAB (SOLOWAYS) |
| Drug class | Immunomodulator / Macrophage activator |
| Target | Macrophage receptor (CD14/TLR4 complex proposed) |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology |
| Phase | Phase 3 |
Mechanism of action
GcMAF is a naturally occurring protein derivative that binds to macrophage receptors and stimulates their activation, enhancing phagocytosis and cytokine production. This mechanism is proposed to boost innate immunity against cancer cells and potentially viral infections. The protein is derived from vitamin D-binding protein (Gc-protein) and is thought to work by restoring immune function in patients with compromised macrophage activity.
Approved indications
- Advanced cancer (various solid tumors and hematologic malignancies)
- Chronic viral infections
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Flu-like symptoms
Key clinical trials
- Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer (PHASE3)
- Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GcMAF injections (100 ng) CI brief — competitive landscape report
- GcMAF injections (100 ng) updates RSS · CI watch RSS
- S.LAB (SOLOWAYS) portfolio CI